Email this article MOLECULAR GENETIC TESTING IN DIAGNOSTICS OF LUNG CANCER AND OVARIAN CARCINOMA WITH THE USAGE OF CYTOLOGICAL SPECIMENS
- Authors: Grigoruk O.G.1,2,3, Pupkova E.I2, Bazulina L.M2, Lazarev A.F1,2,3
-
Affiliations:
- Altai Branch of N.N. Blokhin Russian Cancer Research Center
- Altai Regional Oncology Dispensary
- The Altai State Medical University
- Issue: Vol 22, No 4 (2017)
- Pages: 214-218
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40394
- DOI: https://doi.org/10.18821/1028-9984-2017-22-4-214-218
- ID: 40394
Cite item
Full Text
Abstract
This article presents results of the introduction in practical oncology of molecular genetic investigations performed with the use of tumor DNA cells taken from the cytological specimens. There was investigated the molecular genetic characteristics of cytological specimens from 126 patients. In 80 cases with the proved diagnosis of pulmonary adenocarcinoma (n = 80) EGFR gene mutations were noted in 11.7% cases. KRAS, BRAF and BRCA1/2 gene mutations were determined in 46 women suffering from serous ovarian carcinoma. KRAS gene mutations in cells of ovarian low-grade serous carcinoma were determined in 62.5% of patients, BRAF- in 12.5% cases. BRCA1 gene mutations have been determined in 14.3% cases from the ovarian high-grade serous carcinoma group. In conditions of the presence of the sufficient amount of tumor cells the cytological material is the fully-featured material for molecular genetic investigations. The investigation both of EGFR gene mutations in pulmonary adenocarcinoma cases and KRAS, BRAF, BRCA1/2 gene mutations with serous ovarian carcinoma are mandatory in the appointment of targeted therapy.
Full Text
##article.viewOnOriginalSite##About the authors
Olga G. Grigoruk
Altai Branch of N.N. Blokhin Russian Cancer Research Center; Altai Regional Oncology Dispensary; The Altai State Medical University
Email: cytolakod@rambler.ru
MD, PhD, DSc, Head of the Clinical Laboratory Diagnostics Department (for Carrying out Cytological Research Methods) of the Altai Regional Oncological Dispensary; Barnaul, 656049, Russian Federation 656049, Barnaul, Russian Federation; Barnaul, 656049, Russian Federation; Barnaul, 656038, Russian Federation
E. I Pupkova
Altai Regional Oncology DispensaryBarnaul, 656049, Russian Federation
L. M Bazulina
Altai Regional Oncology DispensaryBarnaul, 656049, Russian Federation
A. F Lazarev
Altai Branch of N.N. Blokhin Russian Cancer Research Center; Altai Regional Oncology Dispensary; The Altai State Medical University656049, Barnaul, Russian Federation; Barnaul, 656049, Russian Federation; Barnaul, 656038, Russian Federation
References
- Злокачественные опухоли. Международный ежеквартальный научно-практический журнал по онкологии. 2015; (4, спец. выпуск): 1-456. doi: 10.18027/2224-5057-2015-4s - 456
- Paez J.G., Jдnne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676): 1497-500.
- Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I. et al. EGF receptor gene mutations are common in lung cancers from «never smokers» and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA. 2004; 101(36): 13306-11.
- Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361(10): 947-57. doi: 10.1056/NEJMoa0810699
- Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E. et al. Spanish Lung Cancer Group in collaboration with Groupe Franзais de Pneumo-Cancйrologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3): 239-46. doi: 10.1016/S1470-2045(11)70393-X
- Имянитов Е.Н. Наследственный рак молочной железы. Практическая онкология. 2010; 11(4): 258-66.
- Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012; 460(3): 237-49. doi: 10.1007/s00428-012-1203-5
- Kaldawy A., Segev Y., Lavie O., Auslender R., Sopik V., Narod S.A. Low-grade serous ovarian cancer: A review. Gynecol. Oncol. 2016; 143(2): 433-8. doi: 10.1016/j.ygyno.2016.08.320
- Combe P., Chauvenet L., Lefrere-Belda M.A., Blons H., Rousseau C., Oudard S., et al. Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation. Invest. New Drugs. 2015; 33(6): 1267-70. doi: 10.1007/s10637-015-0297-4
- Byrski T., Gronwald J., Huzarski T., Grzybowska E., Budryk M., Stawicka M. et al. Pathologic complete response rates in young women with BRCA1-positive breast cancer after neoadjuvantchemotherapy. J. Clin. Oncol. 2010; 28(3): 375-9. doi: 10.1200/JCO.2008.20.7019
- Любченко Л.Н., Батенева Е.И., Абрамов И.С., Емельянова М.А., Будик Ю.А., Тюляндина А.С. и др. Наследственный рак молочной железы и яичников. Злокачественные опухоли. 2013; (2): 53-61. doi: 10.18027/2224-5057-2013-2-53-61
- Демидова И.А. Наследственно обусловленный рак яичников. Современная онкология. 2015; 17(3): 70-5.
- Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 2012;366(15):1382-92. doi: 10.1056/NEJMoa1105535
- Торопова Н.Е., Закамова Е.В., Тетерина Ю.Ю., Козлов С.В., Тимофеева Н.В., Морошкина Г.П. и др. Молекулярно-генетические исследования в практике онкологической клиники. Известия Самарского научного центра РАН. 2015; (2-3): 690-6.
- Consensus for EGFR mutation testing in NSCLC: results of European Workshop. J. Thorac. Oncol. 2010; 5: 1706-13.
Supplementary files
